TVTX - שולי רווח נקי ממכירות Travere Therapeutics, Inc.

Travere Therapeutics (TVTX) bases its strategy on developing a portfolio of therapies for rare kidney pathologies. Current net profit margins demonstrate progress toward this goal, with the -23.70 mark reflecting the latest data. Growth is hindered by dependence on regulators and patent rights, although the uniqueness of the drugs helps the company maintain a monopoly status within its niche.
Retrophin (TVTX) - פילוחי מדדים ודוחות פיננסיים

Sales margin measures the share of net profit in total revenue, reflecting the final efficiency of cost management after deducting all operating and tax expenses. By analyzing the net margin percentage, an investor assesses the ability of Travere Therapeutics (TVTX) to convert exclusive rights to the drug Filspari into actual cash flow, given the specific costs associated with bringing orphan drugs to market.